Mesoblast Limited

ASX (AUD): Mesoblast Limited (MSB)

Last Price

1.70

Today's Change

+0.025 (1.48%)

Day's Change

1.64 - 1.75

Trading Volume

5,152,446

Overview

Market Cap

1 Billion

Shares Outstanding

1 Billion

Avg Volume

4,729,422

Avg Price (50 Days)

1.35

Avg Price (200 Days)

1.00

PE Ratio

-10.03

EPS

-0.17

Earnings Announcement

20-Feb-2025

Previous Close

1.68

Open

1.74

Day's Range

1.64 - 1.75

Year Range

0.255 - 1.83

Trading Volume

5,152,446

Price Change Highlight

1 Day Change

1.49%

5 Day Change

7.91%

1 Month Change

35.32%

3 Month Change

76.68%

6 Month Change

44.49%

Ytd Change

459.02%

1 Year Change

349.56%

3 Year Change

5.25%

5 Year Change

-2.01%

10 Year Change

-57.38%

Max Change

175.22%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment